| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $ | – | |
Sells | $ | – |
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at RAPT Therapeutics, Inc. have bought $undefined and sold $undefined worth of RAPT Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at RAPT Therapeutics, Inc. have bought $6.87M and sold $3.41M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $97,612 was made by Robbins Wendye (director) on 2023‑03‑14.
| Increased Positions | 0 | 0% | 0 | 0% |
| Decreased Positions | 0 | 0% | 0 | 0% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
| Total Postitions | 0 | 0% | 0 | 0% |
| Medicxi Ventures Management (Jersey) Ltd | $88,989.00 | 9.98% | 2.79M | 0 | 0% | 2025-09-30 |
| Tcg Crossover Management, Llc | $52,115.00 | 5.84% | 1.64M | 0 | 0% | 2025-09-30 |
| Foresite Capital Management Vi Llc | $49,766.00 | 5.58% | 1.56M | 0 | 0% | 2025-09-30 |
| Rtw Investments, Lp | $46,835.00 | 5.25% | 1.47M | 0 | 0% | 2025-09-30 |
| Orbimed Advisors Llc | $34,609.00 | 3.88% | 1.09M | -555,288 | -33.82% | 2025-09-30 |
| Boone Capital Management Llc | $24,921.00 | 2.8% | 782,461 | +782,461 | New | 2025-09-30 |
| Deep Track Capital, Lp | $23,933.00 | 2.68% | 751,422 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $22,174.00 | 2.49% | 696,188 | -183,861 | -20.89% | 2025-09-30 |
| Nantahala Capital Management, Llc | $19,852.00 | 2.23% | 623,282 | -328,331 | -34.5% | 2025-09-30 |
| Ikarian Capital, Llc | $19,588.00 | 2.2% | 615,000 | +615,000 | New | 2025-09-30 |